Complicated Urinary Tract Infections Pipeline and Clinical Trials Assessment (2023) | Companies- Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals, Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and o

(Albany, 08 June 2023), DelveInsight's "Complicated Urinary Tract Infections Pipeline Insight 2023" report offers extensive knowledge on more than 12+ companies and 12+ pipeline drugs within the landscape of Complicated Urinary Tract Infections research. The Complicated Urinary Tract Infections Pipeline report provides detailed profiles of the Complicated Urinary Tract Infections pipeline drugs, encompassing both Complicated Urinary Tract Infections clinical trials and nonclinical stage products. Additionally, it assesses the Complicated Urinary Tract Infections pipeline therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.

The Complicated Urinary Tract Infections pipeline analysis report for Complicated Urinary Tract Infections emerging drugs offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Complicated Urinary Tract Infections pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, Complicated Urinary Tract Infections clinical trial studies conducted for Complicated Urinary Tract Infections, any obtained Complicated Urinary Tract Infections NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.

To explore more information on the latest breakthroughs in the Complicated Urinary Tract Infections Pipeline treatment landscape of the report, click here @ Complicated Urinary Tract Infections Pipeline Outlook- https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Complicated Urinary Tract Infections Pipeline Report
• DelveInsight's Complicated Urinary Tract Infections Pipeline analysis depicts a robust space with 12+ active players working to develop 12+ pipeline treatment therapies.
• The leading Complicated Urinary Tract Infections Companies are working in the market include Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals, Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and others.
• Promising Complicated Urinary Tract Infections Pipeline Therapies in the various stages of development include Tebipenem Pivoxil Hydrobromide, Sulopenem, Meropenem, Cefepime-zidebactam (FEP-ZID), Doripenem, Eravacycline, Ertapenem, and others.
• Sulopenem is an orally bioavailable, broad-spectrum penem β-lactam antibiotic which is being developed for the treatment of infections caused by multi-drug resistant bacteria. Sulopenem was discovered in the laboratories of Pfizer Inc. in the 1980s and was first developed with an intravenous (IV) formulation only. The company completed an extensive pre-clinical program, followed by human studies. Later, an oral formulation was developed and tested in Phase I and Phase II trials. In May 2022, Iterum Therapeutics plc announced it met with the US Food and Drug Administration ("FDA") on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company's new drug application ("NDA") for oral sulopenem etzadroxil-probenecid ("oral sulopenem") for the treatment of uncomplicated urinary tract infections ("uUTI"). Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment uncomplicated urinary tract infections.
• Spero Therapeutics is developing tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) as an oral antibiotic for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) to help patients avoid hospitalizations (stay at home) and/or transition patients home after IV therapy (get home). In September 2020, tebipenem HBr completed a pivotal Phase III trial, ADAPT-PO, for the treatment of cUTI, including acute pyelonephritis (AP). ADAPT-PO is a landmark trial that is the first ever to test an all oral regimen against an all intravenous (IV) regimen for the treatment of cUTI. The global, randomized, placebo-controlled ADAPT-PO trial evaluated the safety and efficacy of tebipenem HBr in hospitalized adult patients with cUTI or AP. Data from the trial demonstrated that oral tebipenem HBr was statistically non-inferior to IV ertapenem in the treatment of patients with cUTI and patients with AP. If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP.Following feedback from the US FDA at Spero's recent Type A meeting, Spero will conduct an additional phase III trial to support the regulatory submission.

Complicated Urinary Tract Infections Overview
Urinary tract infections (UTI) are the most common bacterial infections involving lower (cystitis, prostatitis) or upper (pyelonephritis, renal abscess, perinephric abscess) urinary tract. Differentiation of complicated and uncomplicated UTI is usually based on the presence of structural or functional urinary tract abnormalities, which can increase the risk of treatment failure and development of serious complications.

For further information, refer to the detailed Complicated Urinary Tract Infections Unmet Needs, Complicated Urinary Tract Infections Market Drivers, and Complicated Urinary Tract Infections Market Barriers, click here for Complicated Urinary Tract Infections Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Complicated Urinary Tract Infections Emerging Drugs Profile
• Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
• Sulopenem: Iterum Therapeutics

Complicated Urinary Tract Infections Pipeline Therapeutics Assessment
There are approx. 12+ Complicated Urinary Tract Infections companies which are developing the therapies for Complicated Urinary Tract Infections. The Complicated Urinary Tract Infections companies which have their Complicated Urinary Tract Infections drug candidates in the most advanced stage, i.e. Phase III include, Spero Therapeutics.

Request a sample and discover the recent advances in Complicated Urinary Tract Infections Ongoing Clinical Trial Analysis and Medications, click here @ Complicated Urinary Tract Infections Treatment Landscape- https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Complicated Urinary Tract Infections Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Complicated Urinary Tract Infections Therapeutics Market include-
Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals, Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and others.

Dive deep into rich insights for drugs for Complicated Urinary Tract Infections Pipeline, click here @ Complicated Urinary Tract Infections Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Complicated Urinary Tract Infections Pipeline Report
• Coverage- Global
• Complicated Urinary Tract Infections Companies- Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals, Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and others.
• Complicated Urinary Tract Infections Pipeline Therapies- Tebipenem Pivoxil Hydrobromide, Sulopenem, Meropenem, Cefepime-zidebactam (FEP-ZID), Doripenem, Eravacycline, Ertapenem, and others
• Complicated Urinary Tract Infections Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Complicated Urinary Tract Infections Mergers and acquisitions, Complicated Urinary Tract Infections Licensing Activities @ Complicated Urinary Tract Infections Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Complicated Urinary Tract Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. ETX0282CPDP: Entasis Therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Complicated Urinary Tract Infections Key Companies
17. Complicated Urinary Tract Infections Key Products
18. Complicated Urinary Tract Infections- Unmet Needs
19. Complicated Urinary Tract Infections- Market Drivers and Barriers
20. Complicated Urinary Tract Infections- Future Perspectives and Conclusion
21. Complicated Urinary Tract Infections Analyst Views
22. Complicated Urinary Tract Infections Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.